AbstractThe bispecific antibody tarlatamab recruits T cells to cancers expressing the neuroendocrine epitope delta-like ligand 3 (DLL3). Tarlatamab is effective in small cell lung cancer (SCLC), but c...

A deep-learning approach applied to routine CT scans is used to quantify the health of the thymus in a cohort of patients with cancer, and shows that thymic function is associated with immunotherapy&n...

Homozygous loss of MTAP (methylthioadenosine phosphorylase) occurs in approximately 15% of cancers and leads to partial PRMT5 inhibition, creating a selective vulnerability to PRMT5 inhibitors. The fr...

Wang et al. conducted an open-label, multicenter phase 1a/b study to evaluate the safety, pharmacokinetics, and efficacy of HS-20093 in patients with advanced solid tumors. HS-20093 demonstrated a man...

Combining radiotherapy (RT) with targeted agents may lead to improved treatment outcomes across various tumor types. However, there is a risk of increased toxicity. Unfortunately, high-quality toxicit...

Survival in patients with cancer, affected by myriad factors, is notoriously difficult to predict. But while oncologists find it hard to communicate the uncertainty, patients are the ones who must ...

Immune checkpoint inhibitors have revolutionized cancer treatment but can trigger immune-related encephalitis. This article reports one of the largest case

Thyroid transcription factor-1 (TTF-1) expression, routinely assessed through immunohistochemistry (IHC) in the diagnostic evaluation of lung adenocarcinomas (LUAD), is negative (TTF-1Neg) in ∼15-20% ...

Rearranged during transfection (RET) gene fusions are rare but actionable oncogenic drivers in non-small cell lung cancer (NSCLC), occurring in approximately 1.0%–2% of cases and predominantly in lung...

Osimertinib represents the standard of care for the treatment of advanced non-small-cell lung cancer (NSCLC) harboring classical epidermal growth fact…

MISSIONE INTERNAZIONALE – SALPIAMO PER GAZAMentre il genocidio in corso a Gaza peggiora di giorno in giorno e le istituzioni restano in silenzio, persone da tutto il mondo si stanno mobilitando per co...

The current standard of care for fit patients with unresectable stage III NSCLC involves concurrent chemoradiation (CRT) followed by durvalumab. Disease recurrence occurs in approximately 2/3 of patie...

For epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC), overexpression of c-MET has been associated with resistance to EGFR tyrosine kinase inhibitors (TKIs). Upon prog...

Median overall survival improvement expected to exceed one year First and only regimen with a survival benefit over current standard of care in first-line treatment of EGFR-mutated lung cancer

Cachexia is a common complication of cancer and is associated with an increased risk of death. The level of growth differentiation factor 15 (GDF-15), a circulating cytokine, is elevated in cancer ...

Cell-free DNA (cfDNA) sequence analysis to screen for fetal aneuploidy can incidentally detect maternal cancer. Additional data are needed to identify DNA-sequencing patterns and other biomarkers t...

Multi-omic studies have identified three molecular separated pulmonary carcinoid (PC) subgroups (A1, A2, B) with distinctive mRNA expression profiles (e.g. OTP/ASCL1/HNF1A). We aimed to establish an i...

Lorlatinib is a potent, brain-penetrant, third-generation inhibitor of anaplastic lymphoma kinase (ALK) and ROS1 tyrosine kinases with broad coverage of ALK resistance mutations. We present overall su...

Osimertinib represents the standard of care for the treatment of advanced non-small-cell lung cancer (NSCLC) harboring classical epidermal growth fact…